PMC:7755033 / 16789-17166 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"336","span":{"begin":65,"end":67},"obj":"Species"},{"id":"338","span":{"begin":265,"end":273},"obj":"Chemical"},{"id":"339","span":{"begin":301,"end":309},"obj":"Chemical"}],"attributes":[{"id":"A336","pred":"tao:has_database_id","subj":"336","obj":"Tax:126910"},{"id":"A338","pred":"tao:has_database_id","subj":"338","obj":"MESH:D006859"},{"id":"A339","pred":"tao:has_database_id","subj":"339","obj":"MESH:D006859"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"index.html)\n\n2.2.1. Lipinski’s rule of five\nThe druglikeness of WS phytoconstituents was also assessed using Lipinski’s rule of five (Ertl et al., 2000; Lipinski et al., 1997; Veber et al., 2002). The parameters of druglikeness such as MW ≤500, logP ≤5, number of hydrogen bond donors (NOHNH) ≤5 and hydrogen bond acceptor sites (NON)≤10, topological polar surface area (TPSA)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T140","span":{"begin":13,"end":19},"obj":"Sentence"},{"id":"T141","span":{"begin":21,"end":44},"obj":"Sentence"},{"id":"T142","span":{"begin":45,"end":197},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"index.html)\n\n2.2.1. Lipinski’s rule of five\nThe druglikeness of WS phytoconstituents was also assessed using Lipinski’s rule of five (Ertl et al., 2000; Lipinski et al., 1997; Veber et al., 2002). The parameters of druglikeness such as MW ≤500, logP ≤5, number of hydrogen bond donors (NOHNH) ≤5 and hydrogen bond acceptor sites (NON)≤10, topological polar surface area (TPSA)"}